EuropaBio and EU Commission put white biotech in front of investment community

White biotech companies present themselves to investors in the first roundtable of its kind

26-Nov-2004

EuropaBio and the EU Commission have for the first time created a roundtable where the white biotech community will have the opportunity to present to a group of pan-European investors. The roundtable will take place on 30 November as part of the 8th Biotech & Finance Forum in Barcelona, on the 29th of November.

Within the roundtable such leading European companies as Novozymes will present the rapid developments being seen in the white biotech sector. The objective is to inform private investors that Europe's emerging small and medium sized white biotech enterprises are an excellent opportunity for investment. A selected handful of top white biotech companies will be presenting.

The Organisation for Economic Co-operation and Development (OECD) report on biomass and agriculture, along with the EC, render white biotech as one of the most prominent sources for a sustainable energy market in Europe. And recent McKinsey & Co. report shows that white biotech could be applied in the production of 10 to 20% of all chemicals sold by the year 2010. The generated added value in the chemistry industry alone is estimated to amount up to EUR 11 to 22 billion per annum by 2010.

"There are so many new possibilities to apply this technology, from setting new environmental standards for the manufacturing of textiles, leathers and paper to completely new products like biodegradable plastics," says Steen Riisgaard, Chairman of EuropaBio's Industrial Biotech Council and Vice Chairman of EuropaBio - the EU association of bioindustries.

https://www.bionity.com/en/news/41125/europabio-and-eu-commission-put-white-biotech-in-front-of-investment-community.html